Unusual sites of Ewing sarcoma (ES): A retrospective multicenter 30-year experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG)

Massimo Berger, Franca Fagioli, Massimo Abate, Riccardo Riccardi, Arcangelo Prete, Raffaele Cozza, Rossella Bertulli, Marta Podda, Stefano Ferrari, Roberto Luksch

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of this study was to describe the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG) experience from 1980 to 2009 on 112 patients with Ewing sarcoma (ES) occurring in unusual sites such as the craniofacial bones (CF), hands or feet (HF), or the mobile spine. These sites were grouped because their rarity as ES localisations. Patient and methods: Twenty-six patients had CF ES (23%), 37 patients had HF ES (33%) and 49 patients had mobile spine ES (44%). A total of 26 patients presented with synchronous metastatic disease (23%). The local treatment with surgery and/or radiotherapy differed among ES sites. Systemic therapy was administrated according to the protocols in use over the years. Results: From the data available, the histological/radiological response was higher for HF-patients even not statistical significant (good responders: CF 41%, HF 65% and mobile spine 39%, P = 0.NS) and the probability of achieving complete response was similar among the three sites (CF 87%, HF 83% and spine 74%, P = 0.44). Ten year overall survival (OS) was 61% (95% confidence interval [CI] 39-82), 63% (95% CI 37-89) and 64% (95% CI 49-79) for CF, HF or vertebral ES, respectively (P = NS). Ten year OS for non-metastatic patients was 60% (95% CI 36-83), 75% (95% CI 56-94) and 67% (95% CI 47-89) for CF, HF and mobile spine patients respectively (P = NS). Ten year OS was 45% (95% CI, 31-84) and 70% (95% CI, 61-85, [p = 0.01]) for metastatic and localised ES, respectively. Conclusions: The probability of successful treatment did not differ from ES of the extremities. Furthermore, our series confirm the poor prognosis for patients with metastatic disease. Our data do not strengthen the need for a specific protocol for unusual site ES.

Original languageEnglish
Pages (from-to)3658-3665
Number of pages8
JournalEuropean Journal of Cancer
Volume49
Issue number17
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Ewing's Sarcoma
Hematology
Sarcoma
Foot Bones
Hand Bones
Pediatrics
Confidence Intervals
Spine
Survival
Foot
Sarcoma 37
Hand
Radiotherapy
Therapeutics
Extremities
Bone and Bones

Keywords

  • Ewing sarcoma
  • Unusual sites

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Unusual sites of Ewing sarcoma (ES) : A retrospective multicenter 30-year experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG). / Berger, Massimo; Fagioli, Franca; Abate, Massimo; Riccardi, Riccardo; Prete, Arcangelo; Cozza, Raffaele; Bertulli, Rossella; Podda, Marta; Ferrari, Stefano; Luksch, Roberto.

In: European Journal of Cancer, Vol. 49, No. 17, 11.2013, p. 3658-3665.

Research output: Contribution to journalArticle

@article{b676f31c4309443faecae25a0871e358,
title = "Unusual sites of Ewing sarcoma (ES): A retrospective multicenter 30-year experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG)",
abstract = "Purpose: The aim of this study was to describe the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG) experience from 1980 to 2009 on 112 patients with Ewing sarcoma (ES) occurring in unusual sites such as the craniofacial bones (CF), hands or feet (HF), or the mobile spine. These sites were grouped because their rarity as ES localisations. Patient and methods: Twenty-six patients had CF ES (23{\%}), 37 patients had HF ES (33{\%}) and 49 patients had mobile spine ES (44{\%}). A total of 26 patients presented with synchronous metastatic disease (23{\%}). The local treatment with surgery and/or radiotherapy differed among ES sites. Systemic therapy was administrated according to the protocols in use over the years. Results: From the data available, the histological/radiological response was higher for HF-patients even not statistical significant (good responders: CF 41{\%}, HF 65{\%} and mobile spine 39{\%}, P = 0.NS) and the probability of achieving complete response was similar among the three sites (CF 87{\%}, HF 83{\%} and spine 74{\%}, P = 0.44). Ten year overall survival (OS) was 61{\%} (95{\%} confidence interval [CI] 39-82), 63{\%} (95{\%} CI 37-89) and 64{\%} (95{\%} CI 49-79) for CF, HF or vertebral ES, respectively (P = NS). Ten year OS for non-metastatic patients was 60{\%} (95{\%} CI 36-83), 75{\%} (95{\%} CI 56-94) and 67{\%} (95{\%} CI 47-89) for CF, HF and mobile spine patients respectively (P = NS). Ten year OS was 45{\%} (95{\%} CI, 31-84) and 70{\%} (95{\%} CI, 61-85, [p = 0.01]) for metastatic and localised ES, respectively. Conclusions: The probability of successful treatment did not differ from ES of the extremities. Furthermore, our series confirm the poor prognosis for patients with metastatic disease. Our data do not strengthen the need for a specific protocol for unusual site ES.",
keywords = "Ewing sarcoma, Unusual sites",
author = "Massimo Berger and Franca Fagioli and Massimo Abate and Riccardo Riccardi and Arcangelo Prete and Raffaele Cozza and Rossella Bertulli and Marta Podda and Stefano Ferrari and Roberto Luksch",
year = "2013",
month = "11",
doi = "10.1016/j.ejca.2013.06.045",
language = "English",
volume = "49",
pages = "3658--3665",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "17",

}

TY - JOUR

T1 - Unusual sites of Ewing sarcoma (ES)

T2 - A retrospective multicenter 30-year experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG)

AU - Berger, Massimo

AU - Fagioli, Franca

AU - Abate, Massimo

AU - Riccardi, Riccardo

AU - Prete, Arcangelo

AU - Cozza, Raffaele

AU - Bertulli, Rossella

AU - Podda, Marta

AU - Ferrari, Stefano

AU - Luksch, Roberto

PY - 2013/11

Y1 - 2013/11

N2 - Purpose: The aim of this study was to describe the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG) experience from 1980 to 2009 on 112 patients with Ewing sarcoma (ES) occurring in unusual sites such as the craniofacial bones (CF), hands or feet (HF), or the mobile spine. These sites were grouped because their rarity as ES localisations. Patient and methods: Twenty-six patients had CF ES (23%), 37 patients had HF ES (33%) and 49 patients had mobile spine ES (44%). A total of 26 patients presented with synchronous metastatic disease (23%). The local treatment with surgery and/or radiotherapy differed among ES sites. Systemic therapy was administrated according to the protocols in use over the years. Results: From the data available, the histological/radiological response was higher for HF-patients even not statistical significant (good responders: CF 41%, HF 65% and mobile spine 39%, P = 0.NS) and the probability of achieving complete response was similar among the three sites (CF 87%, HF 83% and spine 74%, P = 0.44). Ten year overall survival (OS) was 61% (95% confidence interval [CI] 39-82), 63% (95% CI 37-89) and 64% (95% CI 49-79) for CF, HF or vertebral ES, respectively (P = NS). Ten year OS for non-metastatic patients was 60% (95% CI 36-83), 75% (95% CI 56-94) and 67% (95% CI 47-89) for CF, HF and mobile spine patients respectively (P = NS). Ten year OS was 45% (95% CI, 31-84) and 70% (95% CI, 61-85, [p = 0.01]) for metastatic and localised ES, respectively. Conclusions: The probability of successful treatment did not differ from ES of the extremities. Furthermore, our series confirm the poor prognosis for patients with metastatic disease. Our data do not strengthen the need for a specific protocol for unusual site ES.

AB - Purpose: The aim of this study was to describe the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG) experience from 1980 to 2009 on 112 patients with Ewing sarcoma (ES) occurring in unusual sites such as the craniofacial bones (CF), hands or feet (HF), or the mobile spine. These sites were grouped because their rarity as ES localisations. Patient and methods: Twenty-six patients had CF ES (23%), 37 patients had HF ES (33%) and 49 patients had mobile spine ES (44%). A total of 26 patients presented with synchronous metastatic disease (23%). The local treatment with surgery and/or radiotherapy differed among ES sites. Systemic therapy was administrated according to the protocols in use over the years. Results: From the data available, the histological/radiological response was higher for HF-patients even not statistical significant (good responders: CF 41%, HF 65% and mobile spine 39%, P = 0.NS) and the probability of achieving complete response was similar among the three sites (CF 87%, HF 83% and spine 74%, P = 0.44). Ten year overall survival (OS) was 61% (95% confidence interval [CI] 39-82), 63% (95% CI 37-89) and 64% (95% CI 49-79) for CF, HF or vertebral ES, respectively (P = NS). Ten year OS for non-metastatic patients was 60% (95% CI 36-83), 75% (95% CI 56-94) and 67% (95% CI 47-89) for CF, HF and mobile spine patients respectively (P = NS). Ten year OS was 45% (95% CI, 31-84) and 70% (95% CI, 61-85, [p = 0.01]) for metastatic and localised ES, respectively. Conclusions: The probability of successful treatment did not differ from ES of the extremities. Furthermore, our series confirm the poor prognosis for patients with metastatic disease. Our data do not strengthen the need for a specific protocol for unusual site ES.

KW - Ewing sarcoma

KW - Unusual sites

UR - http://www.scopus.com/inward/record.url?scp=84886795431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886795431&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2013.06.045

DO - 10.1016/j.ejca.2013.06.045

M3 - Article

C2 - 23890769

AN - SCOPUS:84886795431

VL - 49

SP - 3658

EP - 3665

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 17

ER -